Nimotuzumab, a fully-human antibody against EGFR, increases clinical responses to chemo-radiotherapy (59.5% versus 34.2%), has a lower incidence of AEs, and has also been approved for HNSCC treatment (Rodríguez et al., 2010). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.